Hypothesis

Chronic inflammaging produced by senescent immune cells reprograms hematopoietic stem cells (HSCs) via metabolite‑mediated HIF‑1α stabilization, locking the hematopoietic system into a myeloid‑biased, immunosuppressive state that further fuels senescent cell accumulation. This creates a self‑reinforcing loop where immune senescence drives hematopoietic aging, which in turn accelerates immune senescence. Senolytic clearance of senescent immune cells will reduce circulating succinate and lactate, lower HIF‑1α activity in HSCs, restore lymphoid‑myeloid balance, and delay multimorbidity.

Mechanistic Reasoning

• Senescent immune cells secrete IL‑6, TNF‑α, and IL‑1β, which elevate extracellular succinate and lactate in the bone marrow niche (see [4]).
• Succinate inhibits prolyl hydroxylases, stabilizing HIF‑1α even under normoxia, shifting HSC metabolism toward glycolysis and promoting myeloid differentiation (novel link).
• HIF‑1α directly binds promoters of myeloid transcription factors (PU.1, C/EBPα) and represses lymphoid programs (e.g., Ikaros), imprinting an epigenetic signature detectable by increased H3K27ac at myeloid enhancers.
• The resulting myeloid‑skewed output generates more neutrophils and monocytes that, when aged, become senescent themselves, amplifying SASP and completing the loop.
• Removing senescent immune cells with senolytics lowers succinate/lactate, reduces HIF‑1α, allows NAD+‑dependent sirtuin activity to deacetylate HIF‑1α, and restores balanced HSC output.

Testable Predictions

1. Metabolite measurement – Aged mice will show higher bone‑marrow succinate and lactate levels than young controls; senolytic treatment (dasatinib + quercetin) will normalize these metabolites.
2. HIF‑1α activity – Flow cytometry for HIF‑1α+ HSCs will be increased in aged marrow and decreased after senolytics.
3. Epigenetic profiling – ATAC‑seq and H3K27ac ChIP‑seq of HSCs will reveal myeloid‑biased chromatin accessibility in aged mice, reversible by senolytics.
4. Functional output – Competitive transplantation of HSCs from senolytic‑treated aged donors into irradiated young recipients will yield higher lymphoid‑to‑myeloid ratios and improved vaccine responses compared with HSCs from untreated aged donors.
5. Phenotypic rescue – Long‑term senolytic treatment will delay frailty indices, reduce tissue SASP markers, and extend median lifespan in asexually aged mouse models.

Falsifiability

If senolytic treatment fails to reduce bone‑marrow succinate/lactate, does not lower HIF‑1α in HSCs, or does not restore lymphoid‑myeloid balance despite clearing senescent immune cells, the hypothesis that inflammaging‑driven metabolic reprogramming of HSCs is a central driver of immune senescence would be refuted.

References (inline)

• Transplanting an aged immune system into young mice induces senescence and damage in solid organs [1].
• T cells with dysfunctional mitochondria act as aging accelerators that directly instigate multiple age‑related diseases [2].
• Impaired immune surveillance accelerates the accumulation of senescent cells [3].
• Senescent cells secrete factors that induce the NAD‑degrading enzyme CD38 in other cells [4].
• Senolytics prevent mitochondrial DNA‑induced inflammation and dampen age‑specific immune responses, improving survival of transplanted aged organs [5].
• A specific subset of T helper cells with cytotoxic capabilities accumulates with age and slows aging by clearing harmful senescent cells [6].